Well-differentiated papillary mesothelioma (WDPM) is an uncommon mesothelial proliferation that is most commonly encountered as an incidental finding in the peritoneal cavity. There is controversy in the literature about whether WDPM is a neoplasm or a reactive process, and if neoplastic, whether it is a variant or precursor of epithelial malignant mesothelioma or is a different entity. Using whole exome sequencing of five WDPM of the peritoneum, we have identified distinct mutations in EHD1, ATM, FBXO10, SH2D2A, CDH5, MAGED1, and TP73 shared by WDPM cases but not reported in malignant mesotheliomas. Furthermore, we show that WDPM is strongly enriched with C>A transversion substitution mutations, a pattern that is also not found in malignant mesotheliomas. The WDPMs lacked alterations involving BAP1, SETD2, NF2, CDKN2A/B, LASTS1/2, PBRM1 and SMARCC1 that are frequently altered in malignant mesotheliomas. We conclude that WDPMs are genetically distinct from malignant mesotheliomas, and based on observed mutations do not appear to be precursors of malignant mesotheliomas.
Introduction
Well-differentiated papillary mesothelioma (WDPM) is a morphologically distinctive papillary proliferation of mesothelial cells that is most commonly encountered as an incidental finding in the peritoneal cavity, and less often in the pleural cavity, pericardium, and tunica vaginalis. These lesions may be single or multiple, but by definition do not invade the underlying stroma and usually behave in a benign or indolent fashion, sometimes persisting for many years 1 . However, the nature of WDPM is disputed, with theories ranging from a reactive non-neoplastic process to a benign tumor, to a variant and/or precursor of epithelial malignant mesotheliomas 2 . To add further confusion, unequivocal invasive malignant mesotheliomas can have areas that mimic WDPM. Since malignant mesotheliomas are aggressive tumors, the distinction from WDPM is important, but WDPM are sometimes treated with debulking cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) as if they were mesotheliomas 3 .
Genome-wide sequencing analyses of malignant mesotheliomas have revealed frequently observed genomic aberrations such as loss of function mutation and/or copy number alterations/deletion of BAP1, SETD2, CDKN2A, and NF2 [4] [5] [6] . Studies analyzing WDPM using DNA sequencing technology are limited. Case studies have reported WDPMs with somatic mutation of E2F1 7 , heterozygous loss of
, and germline BAP1 mutation 9 , which if correct would suggest that they may be variants of malignant mesothelioma. Nevertheless, using immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH), Lee et . Furthermore, due to lack of matched germline control samples from the WDPM cases, we used genomic DNA samples from blood of a cohort of peritoneal mesothelioma patients as germline control samples. We filtered out any variants that were also present in these control samples 6 . In this way, we excluded any potential germline variants as well as false positive calls and obtained highly confident variants of WDPM. Based on the variant allele frequency (VAF), the somatic mutations identified in WDPM were clustered into different groups using the R-package Maftools 14 .
Copy number aberration (CNA) calls
Copy number changes were assessed using Nexus Copy Number Discovery Edition Version 8.0
(BioDiscovery, Inc., El Segundo, CA). Nexus NGS functionality with the FASST2 Segmentation algorithm was used to make copy number calls (a Circular Binary Segmentation/Hidden Markov Model approach). The significance threshold for segmentation was 5x10 −6 with a minimum of 3 probes per segment and a maximum probe spacing of 1000 between adjacent probes before breaking a segment.
The log ratio thresholds for single copy gain and single copy loss were set at +0.2 and −0.2, respectively. The log ratio thresholds for homozygous gain/loss were set at +0.6 and −1.0, respectively.
The tumor BAM files were processed and compared with BAM files from normal tissue pool as reference control. Reference reads per CN point (window size) was set to 8000. We used the Genomic Identification of Significant Targets in Cancer (GISTIC) 15 algorithm in Nexus to identify significantly amplified or deleted regions across the genome. The amplitude of each aberration is assigned a G-score as well as a frequency of occurrence for multiple samples. False Discovery Rate (FDR) q-values for the aberrant regions was set to a threshold of 0.15.
Mutational signature analysis
We used deconstructSigs 16 software, a multiple regression approach to statistically quantify the contribution of mutational signatures for each tumor. The 30 mutational signatures were obtained from the COSMIC mutational signature database 17 (https://cancer.sanger.ac.uk/cosmic/signatures). Only non-6 silent somatic mutations were used to obtain the mutational signatures. In brief, deconstructSigs attempts to recreate the mutational pattern using the trinucleotide mutation context from the input sample that closely resembles each of the 30 mutational signatures from COSMIC mutational signature database. In this process, each mutational signature is assigned a weight normalized between 0 to 1 indicating its contribution. Only those mutational signatures with a weight more than 0.06 were considered for analysis.
Pathway enrichment analysis
The mutated genes were tested for enrichment against signaling pathways present in KEGG 18 
Peritoneal mesothelioma datasets
We utilized DNA sequencing datasets of two publicly available patient cohorts of peritoneal mesothelioma -VPC cohort 6 and AACR Project GENIE Cohort 20 . We used mutation and copy number profiles from both datasets for comparison with the genomic profiles of WDPM cases. AACR GENIE Project Data: Version 5.0 was downloaded from https://www.synapse.org/#!Synapse:syn7222066.
Results

Histopathological features of WDPM
All five WDPM cases were incidental findings in the peritoneum detected during surgery for another process and all were solitary lesions. All of these five cases had the typical features described for WDPM 21 ; i.e. a papillary architecture with a single layer of covering bland mesothelial cells and myxoid cores in the papillae (Fig. 1) .
Mutational landscape of WDPM
We performed high-coverage whole exome sequencing of five WDPMs from FFPE samples. We achieved a mean sequencing reads coverage of 87x-117x, with at least 20-45% of targeted bases having a coverage of 100x (Supplementary Table 1 ). Due to papillary architecture, the tumor cellularity of the WDPM tissues were estimated to be about 50% (Supplementary Table 2 ). Although, the high coverage sequencing provides us an opportunity to detect higher proportions of mutations, the normal tissue admixture lowers the mutation detection sensitivity. To overcome this challenge, we implemented strict mutation filtering criteria as described in the Methods section and retained only high confident mutation calls for downstream analysis.
Analysis of the mutational patterns in WDPM revealed a strong enrichment of C>A transversion substitution mutation ( Fig. 2A) . Using the software deconstructSigs 16 , we evaluated the characteristic mutation patterns in WDPM against the mutational signature obtained from the COSMIC mutational signature database 17 . Intriguingly, we identified consistent patterns of nucleotide substitution mutation associated with WDPM. Notably, we found that mutational signature 24 is significantly operative in all five WDPM cases (Fig. 2B) . In addition to this, mutational signature 21, and 28 were also observed in the WDPM cases.
We identified 461 unique non-silent mutations across five WDPM samples affecting 297 unique protein coding genes (Supplementary Table 3 ). Patient WDPM-04 had the highest mutation burden and WDPM-01 had the least. Two genes -FBXO10 and SH2D2A, were mutated in all five WDPM cases again displaying consistent mutational patterns (Fig. 2C) . Missense mutation EHD1 D147A in the dynamin protein domain was found in four cases (Fig. 2C-D) . The variant allele frequency (VAF) of EHD1 ranged from 29-43% indicating its likely clonal origin (given that the tumor cellularity of the WDPM tissues were estimated to be about 50%) (Supplementary Figure 1) . Notably, we identified missense mutation in DNA-damage response gene ATM in four cases ( Fig. 2C and 2E Figure 1) . The gene encoding cadherin 5 (CDH5) harbored CDH5 D714E mutations in its C-terminus cadherin protein domain in four cases ( Fig. 2C and 2F) . The VAF of CDH5 also ranged from 26-38% indicating its likely clonal origin (Supplementary Figure 1) . We also identified missense mutation FBXO10 C42F in four cases and FBXO10 C26F in one case ( Fig. 2C and 2G) . Both mutation variants of FBXO10 were present in F-box like protein domain. The VAF of FBXO10 also ranged from 24-37% indicating its likely clonal origin (Supplementary Figure 1) . Similarly, we identified missense mutation SH2D2A G155V in four cases and SH2D2A G155D in one case ( Fig. 2C and 2H) . These variants were located in SH2 protein domain. The VAF of SH2D2A in WDPM-04 was 69% indicating the mutation to be clonal. The VAF of SH2D2A in rest of the four WDPM ranged from 37-47% (Supplementary Figure 1) . Furthermore, we also identified mutations in MAGED1 and TP73 each in four WDPM cases (Fig. 2C) .
Copy Number Aberration landscape of WDPM
The aggregate copy number aberration (CNA) profile of WDPM is shown in Supplementary Figure 2 .
We observed 278 CNA events across all samples (Supplementary Table 4 ). The CNA resulted in alterations of about 4-14% of the protein-coding genomes in WDPM. Patient WDPM-02 had a high copy-number burden and WDPM-03 had the least copy-number burden (Supplementary Figure 2) .
Overall, copy number profiles of WDPM did not show many alterations (Supplementary Figure 3) .
Notably, we found copy number gain of SETDB2 and LAST2, and copy number loss of SMARCA4 and TRAF7 in WDPM-02. We also found copy-number loss of cancer genes such as CCNE1, MAF, MAFB, MYC, ZNF479, MGMT and copy number gain of FOXA2, CDH10, GPC5 in at least two WDPM cases.
Signaling pathways dysregulated in WDPM
To identify signaling pathways dysregulated by mutated genes in WDPM, we performed pathway enrichment analysis using KEGG 18 pathway database (see Methods section). Our analysis revealed that the WDPM mutations target different signaling pathways often dysregulated in cancer ( Fig. 3 and Supplementary 
WDPM is genetically distinct from malignant mesothelioma
Next, we compared the genomic profiles of WDPM with those of malignant peritoneal mesothelioma.
For this, we leveraged the DNA sequencing data from two recently published peritoneal mesothelioma patient cohorts 6, 20 . We first assessed the pattern of mutations in WDPM and peritoneal mesothelioma cases. Intriguingly, we observed that WDPM has a strong enrichment of C>A transversion substitution mutation ( Fig. 2A-B) , whereas, peritoneal mesothelioma has strong enrichment of C>T transition substitution mutation (Supplementary Figure 4) . This mutational pattern in WDPM is different from those reported in pleural 4,5 or peritoneal 6 mesotheliomas.
Notably, we found WDPM specific mutations in EHD1, FBXO10, CHD5, MAGED1, ATM, and TP73
genes that were absent in peritoneal mesothelioma (Fig. 4A) . Although, mutations in EHD1 and ATM genes were each observed in peritoneal mesothelioma, we did not find the WDPM specific EHD1
D147A
, EHD1 A465D , and ATM K2303R mutations in these cases. Interestingly, we did not find any mutations in BAP1, SETD2, TP53, NF2, CDKN2A, and LAST1/2 frequently observed in malignant mesotheliomas (Fig. 4A) . We also did not find mutations in TRAF7 or CDC42 in WDPM, however, TRAF7 mutations were observed in several peritoneal mesothelioma cases. Furthermore, we evaluated the differences in copy number status of genes between WDPM and peritoneal mesothelioma. We did not find any copynumber loss in genes characteristics of malignant mesotheliomas such as BAP1, SETD2, PBRM1, SMARCC1, CDKN2A/B, LATS1/2 and NF2 (Fig. 4B) . TRAF copy-number loss was observed in one WDPM case, whereas, several peritoneal mesothelioma cases harbored TRAF7 copy-number alteration.
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Discussion
In this study, we have investigated the genomic alterations found in a cohort of five WDPM. The tumors analyzed here are clinically typical of the setting in which WDPM is most commonly found; i.e., as an incidental lesion discovered during surgery for another process, and all of the lesions were morphologically characteristic WDPM.
Overall, our results suggest that WDPM are distinctive lesion with their own set of genomic alterations and are genetically quite different from both peritoneal and pleural mesotheliomas. Indeed, our most important finding is the lack of alterations involving BAP1, SETD2, NF2, CDKN2A, PBRM1, and SMARCC1 genes consistently mutated or deleted in malignant mesotheliomas.
We found consistent mutation patterns in five WDPMs with strong enrichment of C>A transversion substitution mutation and COSMIC mutational signature 24. The WDPMs harbored distinct mutations in EHD1, FBXO10, CHD5, MAGED1, ATM, and TP73 genes either in all five or at least four out of five WDPM cases. The COSMIC mutational signature 24 has been shown to be commonly found in certain liver cancers with exposure to carcinogen such as aflatoxin 22 . However, these WDPMs were incidental findings during surgery and any prior exposure to carcinogens (either aflatoxin or asbestos) is extremely unlikely. Mutations and copy-number changes in CDH5 has been previously reported in mesotheliomas 23, 24 , but are uncommon events and were not present in any of our reference mesothelioma datasets (Fig. 3) . CHD5 is known to promote intravasation and stimulates TGF-β driven epithelial-mesenchymal transition (EMT) 25 . EHD1 regulates endocytic recycling process. EHD1 is known to play a key role in transportation of receptors from endosomes into the endocytic recycling compartment (ERC) and from the ERC to the plasma membrane 26 . Moreover, EHD1 has been associated with cell proliferation, apoptosis, metastasis, and drug resistance in breast and non-small cell lung cancer (NSCLC) 27 , but has not been reported to be abnormal in malignant mesotheliomas. FBXO10
binds to the anti-apoptotic oncoprotein BCL-2 and promotes its degradation, thereby initiating cell death in lymphomas 28 . SH2D2A is known to be involved in T-cell activation 29 . Mutations in FBXO10, SH2D2A, and TP73 has not been reported in any malignant mesotheliomas.
Our study confirms lack of copy-number alterations in 
